CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics's stock outlook is bolstered by a significant increase in enterprise value projections, now estimated at $9.46 billion, driven by robust anticipated revenues from its approved drug Casgevy, expected to reach $300 million in 2026 and $630 million in 2027. The company's CAR-T programs have seen a notable valuation increase to $2.51 billion, alongside a dramatic rise in the valuation of zugo-cel in autoimmune diseases to $1.67 billion, indicating strong growth potential ahead of Phase I data. Additionally, CRISPR's in vivo gene editing programs have surged in value to $4.46 billion, underlining the company's commitment to expanding its innovative treatment offerings across multiple high-need therapeutic areas.

Crispr Therapeutics faces a challenging financial outlook due to significant downward revisions in the valuation of its key programs, with the value of its allogeneic CD19 CAR-T zugo-cel (CTX112) reduced from $496 million to $334 million, reflecting lower expected sales for 2030. Additionally, the projected value for VCTX213, aimed at treating Type 1 diabetes, was cut by half from $500 million to $250 million, emphasizing the increasing risks associated with clinical development timelines and regulatory approvals. The company's bear case scenario indicates a potential 30% downside to its projections if Casgevy sales do not accelerate and if earlier-stage programs face discontinuation, resulting in a reduced valuation for Casgevy from $4.70 billion to $1.64 billion.